Format

Send to

Choose Destination

Atelosteogenesis Type 2.

Source

GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.
2002 Aug 30 [updated 2014 Jan 23].

Author information

1
Associate Professor; Head, Division of Molecular Pediatrics, Lausanne University Hospital, Lausanne, Switzerland
2
Laboratory of Molecular Pediatrics, Lausanne University Hospital, Switzerland
3
Senior Lecturer, Division of Molecular Pediatrics, Lausanne University Hospital, Lausanne, Switzerland
4
Professor of Pediatrics, Department of Pediatrics, Lausanne University Hospital, Lausanne, Switzerland

Excerpt

CLINICAL CHARACTERISTICS:

Clinical features of atelosteogenesis type 2 (AO2) include rhizomelic limb shortening with normal-sized skull, hitchhiker thumbs, small chest, protuberant abdomen, cleft palate, and distinctive facial features (midfaceretrusion, depressed nasal bridge, epicanthus, micrognathia). Other typical findings are ulnar deviation of the fingers, gap between the first and second toes, and clubfoot. AO2 is lethal at birth or shortly thereafter because of pulmonary hypoplasia and tracheobronchomalacia.

DIAGNOSIS/TESTING:

The diagnosis of AO2 rests on a combination of clinical, radiologic, and histopathologic features. SLC26A2 (DTDST) is the only gene in which pathogenic variants are known to cause AO2. The diagnosis can be confirmed by molecular genetic testing of SLC26A2.

MANAGEMENT:

Treatment of manifestations: Palliative care for liveborns.

GENETIC COUNSELING:

AO2 is inherited in an autosomal recessive manner. At conception, each sib of a proband with AO2 has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if both pathogenic alleles in the family are known. Ultrasound examination early in pregnancy is a reasonable complement or alternative to molecular genetic prenatal diagnosis.

Copyright © 1993-2018, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

Supplemental Content

Support Center